|
|
The 3rd World Congress on
Controversies in Neurology (CONy)
Clarion Congress Hotel, Prague, Czech Republic, October 8-11, 2009 |
|
| |
| Scientific Program |
 |
|
|
|
PLENARY SESSION & OPENING CEREMONY |
|
Thursday, October 8, 2009 |
|
Chairpersons:
|
A.D. Korczyn, Israel; I. Rektor, Czech Republic; D. Muresanu, Romania
|
|
17:00-17:20 |
Greetings
|
|
17:20-17:40 |
C. Hoschl, Czech Republic
|
|
17:40-18:00 |
R. Bondy, Israel
|
|
18:00-19:00
Capsule: |
Debate: The role of evidence-based medicine (EBM)
EBM has developed into a state-of-the-art way to evaulate new drugs. Does it really provide the promise?
|
|
|
|
|
19:00 |
Welcome Reception |
|
Friday, October 9, 2009 |
|
|
|
|
07:30-08:30 |
GUIDED POSTER TOUR #1 |
|
|
|
|
|
MS: NEW THERAPIES |
|
08:30-10:30 |
|
|
Capsule: |
Pseudobulbar affect (PBA) is an important clinical feature of several neurological diseases, including MS. Its pathogenesis and treatment will be discussed, as well as the role of new therapies.
|
|
Chairpersons:
|
E. Havrdova, Czech Republic; Z. Szolnoki, Hungary
|
|
08:30-09:30 |
Debate: Emotional lability and pseudobulbar affect (PBA) in MS
Sponsored by an unrestricted grant from Avanir Pharmaceuticals
Commentator: A. Miller, Israel |
|
|
|
|
09:30-10:30 |
Debate: Newly emerging therapies: Do their potential benefits outweigh the risks?
Sponsored by an unrestricted grant from Teva - Sanofi Aventis
Yes: R. Milo , Israel
No: O. Stuve , USA
Commentator: P. Vermersch, France |
|
|
|
|
10:30-11:00 |
Coffee Break |
|
|
|
|
|
CLINICAL MANAGEMENT OF MS |
|
11:00-13:00 |
|
|
Capsule: |
The availability of MRI allows clinicians to differentiate various presentations. This is particularly true of clinically isolated syndrome (CIS). However, are all CIS caes to be regarded in the same way? And once treatment is initiated, what is the proper method?
|
|
Chairpersons:
|
J. Losy, Poland; A. Miller, USA
|
|
11:00-12:00 |
Debate: CSF examination is mandatory in every CIS case, regardless of MRI findings
Pro: C. Confavreux, France
Con: E. Havrdova, Czech Republic
Commentator: A. Siva, Turkey |
|
|
|
|
12:00-13:00 |
Debate: Escalation therapy vs. induction therapy
Escalation: X. Montalban, Spain
Induction: G. Comi, Italy
Commentator: N. Putzki, Germany |
|
|
|
|
13:00-14:00 |
Lunch Break |
|
|
|
|
|
MS: PREVENTION AND TREATMENT |
|
14:00-16:00 |
|
|
Capsule: |
In spite of the fact that the etiology of MS is still unknown, data is accumulating, suggesting metabolic changes such as in vitamin D, or viral infections as causes. This suggests potential neuroprotective therapies. On the other extreme, new therapies have developed, which also have significant toxicity, posing questions on how and when these should be used.
|
|
Chairpersons:
|
A.N. Boyko, Russia; Z. Stelmasiak, Poland
|
|
14:00-15:00 |
Debate: Can we prevent MS with early life Vitamin D supplementation and EBV vaccination?
Commentator: I. Steiner, Israel |
|
|
|
|
15:00-16:00 |
Side effects are too significant: G. Comi, Italy
Commentator: H.-P. Hartung, Germany |
|
|
|
|
16:00-16:30 |
Coffee Break |
|
|
|
|
|
NEW PLAYERS IN MS |
|
16:30-18:00 |
|
|
Capsule:
|
Several new drugs are in different stages of development against MS. The up-to-date status of the main ones will be discussed.
|
|
Chairpersons:
|
J. Chapman, Israel; G. Comi, Italy
|
|
|
A. Siva, Turkey |
|
Friday, October 9, 2009 |
|
|
|
|
07:30-08:30 |
GUIDED POSTERS TOUR #1 |
|
|
|
|
|
STROKE PREVENTION |
|
08:30-10:30 |
|
|
Capsule: |
Carotid stenosis is one of the major causes of ischemic stroke. Interpretation of the results of the RCTs on the management of asymptomatic carotid stenosis is still controversial.
|
|
Chairpersons:
|
P. Kalvach, Czech Republic; Z. Trkanjec, Croatia
|
|
08:30-09:30 |
Debate: Asymptomatic carotid stenosis: Intervention of just stick to medical therapy?
Sponsored by an unrestricted grant from Abbott Vascular
Commentator: J. Wojczal, Poland |
|
|
|
|
09:30-10:30 |
Debate: Should mechanical embolectomy devices be used in routine clinical practice?
Yes: M. Bar, Czech Republic
No: P. Sandercock, UK
Commentator: C. Molina, Spain |
|
|
|
|
10:30-11:00 |
Coffee Break |
|
|
|
|
|
INTRACRANIAL BLEEDING |
|
10:30-11:00 |
|
|
Capsule: |
Microbleeds (MB) are detectable on routine MRI studies and may indicate high risk of bleeding. However, it is still unclear whether MB on MRI should guide our antithrombotic therapy. The treatment of subarachnoid hemorrhage has also undergone changes in the past decade, with the development of new technological approaches.
|
|
Chairpersons:
|
E. Ehler, Czech Republic; R. Rangel-Guerra, Mexico
|
|
11:00-12:00 |
Debate: Be careful of CAA and microbleedings when giving anti-thrombosis treatment
Pro: W.W. Zhang, China
Con: C. Cordonnier, France
Commentator: D. Russell, Norway |
|
|
|
|
12:00-13:00 |
Debate: Treatment of aneurysmal subarachnoid hemorrhage
Commentator: J. van Gijn, The Netherlands |
|
|
|
|
13:00-14:00 |
Lunch Break |
|
|
|
|
|
STROKE TREATMENT |
|
14:00-16:00 |
|
|
Capsule: |
The recent ECAS-III trial's result rasied a lot of controversies on whether the therapeutic window should be extended to 4.5 hours. The results of the statins trials (HPS & SPARC L, etc) raised the quesiton on whether statins should be given following all ischemic strokes, regardless of lipid profile, for second stroke prevention.
|
|
Chairpersons:
|
A. Halliday, UK; S. Klimosova, Czech Republic
|
|
14:00-15:00 |
Debate: IV tPA beyond 3 hours: Is it suitable for everyone?
Yes: P. Schellinger, Germany
No: P. Sandercock, UK
Commentator: C. Cordonnier, France |
|
|
|
|
15:00-16:00 |
Debate: Statins should be given to every stroke patient for secondary stroke prevention
No: J. van Gijn, The Netherlands
Commentator: P. Sandercock, UK |
|
|
|
|
16:00-16:30 |
Coffee Break |
|
|
|
|
|
NEW TREATMENTS IN STROKE |
|
16:30-18:30 |
|
|
Capsule: |
Although there has been a substantial progress in the treatment of stroke, in many areas there is still a long way to go. New innovative and exciting approaches for stroke therapy are currently under investigation.
|
|
Chairpersons:
|
D. Bartko, Slovakia; R. Mikulik, Czech Republic
|
|
16:30-17:30 |
Debate: Do animal models fail us in finding new treatments for stroke?
Commentator: P. Sandercock, UK |
|
|
|
|
17:30-18:30 |
NEW PLAYERS IN STROKE |
|
|
CoAxia: P. Schellinger, Germany
|
|
Friday, October 9, 2009 |
|
|
| 07:30-08:30 |
GUIDED POSTER TOUR #1 |
|
|
| Session 9 |
TRADITIONAL VS MODERN THERAPY |
| 08:30-10:30 |
|
| Capsule: |
L-dopa has been established as the gold standard of PD therapy; but older azotheric therapies are still being used extensively. The timing of initation of drug therapy is still debated.
|
|
Chairpersons:
|
E. Martignoni, Italy; J. Roth, Czech Republic
|
| 08:30-09:30 |
Debate: Ayurveda medicine is efficacious therapy in PD
Pro: H. Przuntek, Germany
Con: O. Rascol, France
Commentator: A. Kupsch, Germany |
|
|
| 09:30-10:30 |
Debate: The earlier the better: Treatment should be started immediately on diagnosis
Commentator: E. Ruzicka, Czech Republic |
|
|
| 10:30-11:00 |
Coffee Break |
|
|
| Session 10 |
MODERN THERAPY IN PD: EARLY AND LATE TREATMENT STRATEGIES IN PD
Sponsored by an unrestricted grant from Solvay Pharmaceuticals |
| 11:00-13:00 |
|
| Capsule: |
Early and late treatment strategies in PD are still a cause of disagreement. What are the advantages of each?
|
|
Chairpersons:
|
M. Bares, Czech Republic; C. Falup, Romania
|
| 11:00-12:00 |
Debate: What is the best drug for early PD patients?
Commentator: L. Vecsei, Hungary |
|
|
| 12:00-13:00 |
Debate: What is the best treatment for advanced fluctuating PD
Duodopa: P. Odin, Germany
Apomorphine: R. Hilker, Germany
DBS: E. Seigneuret, France
Commentator: A. Antonini, Italy |
|
|
| 13:00-14:00 |
Lunch Break |
|
|
| Session 11 |
PATHOPHYSIOLOGY OF PD |
| 14:00-16:00 |
|
| Capsule: |
Linkage of new diagnostic procedures and pathophysiological aspects: Can they help us better understand PD pathogenesis?
|
|
Chairpersons:
|
I. Rektor, Czech Republic; E. Sidransky, USA
|
| 14:00-15:00 |
Debate: Substantia nigra hyperecogenicity is a risk marker of PD
Yes: D. Berg, Germany
No: U. Walter, Germany
Commentator: TBA |
|
|
| 15:00-16:00 |
Debate: Does PD have a prion-like pathogenesis?
Yes: R. Hilker, Germany
No: J. Chapman, Israel
Commentator: J. Brotchie, Canada |
|
|
| 16:00-16:30 |
Coffee Break |
|
|
| Session 12 |
COGNITIVE IMPAIRMENT IN PD |
| 16:30-18:30 |
|
| Capsule: |
New findings may sometimes be old. From dementia to long-term modulations in PD
|
|
Chairpersons:
|
Z. Pirtosek, Slovenia; D. Truong, USA
|
| 16:30-17:30 |
Debate: MCI in PD?
|
|
|
| 17:30-18:30 |
NEW PLAYERS IN PD |
|
|
| Saturday , October 10, 2009 |
|
|
| 07:30-08:30 |
GUIDED POSTERS TOUR #2 |
|
|
| Session 13 |
NEUROSURGICAL CONDITIONS |
| 08:30-10:30 |
|
| Capsule: |
This section revies two longs regarding the treatment of seizures. The first debate pertains to the need for prophylactic antiepileptic drug therapy for patients with brain tumors. It is well established that some patients with tumors develop seizures. What is the role of drug therapy before seizures develop? Does it reduce the chance of developing seizures, mitigate the adverse effects of seizures or does it constitute unnecessary hterapy, with the potential for side effects exceeding the potential for benefit? The second topic relates to surgical therapy for epilepsy. Success rates are best when an epileptogenic structural lesion is excised, and are considerably lower when a structural lesion cannot be identified. Should surgery be offered to patients with no evidence for a structural lesion, or be restricted to those who have a high probability of success?
|
|
Chairpersons:
|
M. Brazdil, Czech Republic; M. Levite, Israel
|
| 08:30-09:30 |
Debate: Should prophylactic antiepileptic therapy be prescribed to patients with brain tumors?
Yes: T. Tomson, Sweden
No: E. Beghi, Italy
Commentator: M. Brodie, UK |
|
|
| 09:30-10:30 |
Debate: Should surgery be offered to patients with extra-temporal epilepsy (frontal, parietal, occipital) if the MRI does not show a structural lesion?
Yes: M. Neufeld, Israel
No: M. Sperling, USA
Commentator: I. Rektor, Czech Republic |
|
|
| 10:30-11:00 |
Coffee Break |
|
|
| Session 14 |
MEDICAL TREATMENT OF EPILEPSY |
| 11:00-13:00 |
|
| Capsule: |
Seizures are associated with morbidity, and occasionally, mortality. Medications also are associated with side effects. Is it reasonable to stop antiepileptic medication in a well-controlled patient, knowing that a significant proportion of patients may have a recurrent seizure with its attendant risks? The first debate will reveiw the pros and cons of continuing or stopping medical therapy in well-controlled patients with epilepsy. The second debate addresses the timely issue of use of valporate in women of child bearing age with idiopathic generalized epilepsy. Valproate has been associated with birth defects and cognitive impairment in offspring of women taking that drug while pregnant, yet it is often the agent with the best chance of prodcuing seizure control in many of the idopathic generalized epilepsies. Are there circumstances in which it should be used, and are there ways of using it that minimize its risk?
|
|
Chairpersons:
|
R. Kuba, Czech Republic; W. Theodore, USA
|
| 11:00-12:00 |
Debate: Is AED discontinuation in seizure-free patients dangerous?
Yes: D. Schmidt, Germany
No: E. Beghi, Italy
Commentator: A. Guekht, Russia |
|
|
| 12:00-13:00 |
Debate: Should valproate be prescribed to women of childbearing age with idiopathic generalized epilepsy?
Yes: T. Tomson, Sweden
No: A. Guekht, Russia
Commentator: M. Brodie, UK |
|
|
| 13:00-14:00 |
Lunch Break |
|
|
| Session 15 |
NEW PLAYERS IN EPILEPSY |
| 14:00-16:00 |
|
| Capsule: |
Many individuals with epilepsy continue to experience seizures despite appropriate medical therapy. The first talk will review mechanisms of drug resistance. In response to the lack of adequate response, a new generation of antiepileptic medications is being developed. This session will review some new agents either recently approved or in the pharmaceutical pipeline.
|
|
Chairpersons:
|
P. Mares, Czech Republic; K. Rejdak, Poland
|
| 14:00-14:30 |
|
|
|
|
Chairpersons: |
A. Guekht, Russa; I. Rektor, Czech Republic |
| 14:30-16:00 |
Rufinamide: V. Komarek, Czech Republic
Retigabine: M. Brodie, UK
Carisbamate: B. Chmielewska, Poland
Perampanel: M. Sperling, USA
|
|
|
| 16:00-16:30 |
Coffee Break |
|
|
| Session 16 |
EPILEPSY STUDY CASES |
| 16:30-18:00 |
|
| Capsule: |
This session will be devoted to discussion of ordinary and difficult cases of epilepsy. A distinguished panel will dicuss issues related to diagnosis and management of seizure disorders.
|
|
Presenter: M. Sperling, USA
Panel:
E. Beghi , Italy
M. Brodie, UK
S. J. Czuczwar, Poland
A. Guekht, Russia
M. Neufeld, Israel
I. Rektor, Czech Republic
D. Schmidt, Germany
W. Theodore, USA |
|
Saturday , October 10, 2009 |
|
|
|
|
07:30-08:30 |
GUIDED POSTERS TOUR #2 |
|
|
|
|
|
LATEST ADVANCES IN MIGRAINE RESEARCH AND TREATMENTS
Sponsored by an unrestricted grant from Merck & Co., Inc |
|
08:30-10:30 |
|
| Capsule: |
While migrainous headaches are common and disabling, their pathogenesis and nosology are still unclear. Migraine has a clear genetic background yet it has proven very difficult to pinpoint the genes involved. The clinical manifestations vary considerably within attacks and across patients. This session debates over de role of various neurotransmitters and neuromediators which are involved in the pathophysiology of migraine, such as CGRP receptor antagonists, their effectiveness, safety and tolerability in acute migraine.
The session also presents the most recent data on the genetics of migraine and its implications for novel treatments.
|
|
Chairpersons:
|
H. Bolay, Turkey; R. Hering, Israel
|
|
08:30-09:00
09:00-09:30
09:30-10:00
10:00-10:15
10:15-10:30 |
Unmasking headache myths
M. Ferrari, The Netherands; A. Rapoport, USA
L. Griffiths, Australia
A. Rapoport, USA
T. Ho, USA
Discussion |
|
|
|
|
10:30-11:00 |
Coffee Break |
|
|
|
|
|
HEADACHE THERAPY |
|
11:00-13:00 |
|
|
Capsule: |
Triptans work well, but what is the optimal time to take them? Vitamins may help migraine, but do they decrease disability?
|
|
Chairpersons:
|
M. Kapisyzi, Albania; O. Keller, Czech Republic
|
|
11:00-12:00 |
Debate: Patients with medication overuse headache should undergo withdrawal prior to initiating preventative medication
Pro: N. Mathew, USA
Con: J. Schoenen, Belgium
Commentator: A. Rapoport, USA |
|
|
|
|
12:00-13:00 |
Debate: Vitamin supplementation affects migraine disability
Pro: L. Griffiths, Australia
Con: A. Mauskop, USA
Commentator: J. Schoenen, Belgium |
|
|
|
|
13:00-14:00 |
Lunch Break |
|
|
|
|
|
MIGRAINE TREATMENT AND PATHOPHYSIOLOGY |
|
14:00-16:00 |
|
|
Capsule: |
What are the nuances of treating medication overuse in headache and where does migriane begin? In the brain or outside it?
|
|
Chairpersons:
|
L. Griffiths, Australia; A. Mauskop, USA
|
|
14:00-15:00 |
Triptans must be given early when the headache is mild for them to work well
Pro: D . Mitsikostas, Greece
Con: J. Schoenen, Belgium
Commentator: N. Mathew, USA |
|
|
|
|
15:00-16:00 |
|
|
|
|
|
16:00-16:30 |
Coffee Break |
|
|
|
|
|
IVIG: THE NEW INDICATIONS ON THE BLOCK
Sponsored by an unrestricted grant from Baxter Healthcare |
|
16:30-18:30 |
|
|
Capsule: |
Should chronic inflammatory polyneuropathy (CIDP) be treated with IVIG? Should Alzhiemer's disease be treated with IVIG?
|
|
Chairpersons:
|
E. Nobile-Orazio, Italy; L. Spiru, Romania
|
|
16:30-17:30 |
Debate: AD can be treated by IVIG
Pro: N. Relkin, USA
Con: R. Rusina, Czech Republic
Commentator: U. Bonnucelli, Italy |
|
|
|
|
17:30-18:30 |
Debate: CIDP can be treated permanently with IVIG
Pro: H.-P. Hartung, Germany
Con: I. Wirguin, Israel
Commentator: P. Kennedy, UK
|
| ALZHEIMER'S DISEASE/DEMENTIA & INFECTIOUS DISEASES |
| Saturday , October 10, 2009 |
|
|
07:30-08:30 |
GUIDED POSTERS TOUR #2 |
|
|
|
|
|
DEMENTIA: CAUSES AND DIAGNOSIS |
| 08:30-10:30 |
|
| Capsule: |
The theories designed to understand the pathogenesis of Alzheimer's disease (AD) are still incomplete. Has an infectious etiology been ruled out? Dementia with Lewy bodies is frequently associated with Parkinsonian symptoms. Can imaging help in early diagnosis?
|
|
Chairperson:
|
U. Bonnucelli, Italy; J. Hort, Czech Republic
|
|
08:30-09:30 |
Debate: AD: Are we intervening too late?
Commentator: B.O. Popescu, Romania |
|
|
|
|
09:30-10:30 |
Debate: Infectious agents: A cause of AD?
Commentator: E. Havrdova, Czech Republic |
|
|
|
|
10:30-11:00 |
Coffee Break |
|
|
|
|
|
TREATMENT OF AD |
| 11:00-13:00 |
|
| Capsule: |
Treatment of AD is still not very efficacious. Is it because we do not understand the mechanisms, are the studies not properly designed, or is the timing of intervention wrong?
|
|
Chairpersons:
|
R. Rusina, Czech Republic; M. Windisch, Austria
|
|
11:00-12:00 |
Debate: Why so few new drugs on the market for AD therapy? Is the target the problem or the clinical trails?
The clinical trials are wrong: J. Hort, Czech Republic
Commentator: D. Ames, Australia |
|
|
|
|
12:00-13:00 |
Debate: Is SPECT imaging critical to diagnose dementia with Lewy bodies?
No: M. Bojar, Czech Republic
Commentator: J. Kulisevsky, Spain |
|
|
|
|
13:00-14:00 |
Lunch Break |
|
|
|
|
|
CONTROVERSIES IN NEUROREHABILITATION
Sponsored by an unrestricted grant from The Society for the Study of Neuroprotection and Neuroplasticity |
|
14:00-16:00 |
|
| Capsule: |
Neurorehabilitation is our precious effort towards recovery. It is still unclear how we will get the best of our clinical endeavors. Also, we still have to decide if we listen to intelligent molecules wisdom or to fascinating new technologies or even combine them sometimes.
|
|
Chairpersons:
|
D. Muresanu, Romania; O. Svestkova, Czech Republic
|
|
14:00-15:00 |
Debate: In-patients vs. out-patients neurorehabilitation: Profit and outcome
J.-L. Truelle, France
Commentator: K. von Wild, Germany |
|
|
|
|
15:00-16:00 |
Debate: Neuromodulation in restorative neurology: Deep brain stimulation (DBS) vs. pharmacological treatment in neurorecovery
Commentator: K. von Wild, Germany |
|
|
|
|
16:00-16:30 |
Coffee Break |
|
|
|
|
|
INFECTIONS |
|
16:30-18:30 |
|
|
Capsule: |
In many neurological disorders where the etiology and pathogenesis are unknown, a possible infectious etiology has been proposed and is associated with therapeutic dilemmas. Infections of the nervous system, per se, pose diagnostic and therapeutic challenges. This session focuses on two issues in neurological infections that confront practicing neurologist and have important clinical implications.
|
|
Chairpersons:
|
B.O. Popescu, Romania; G. Ransmayr, Austria
|
|
16:30-17:30 |
Debate: HSV-1 as the causative agent in Bell's palsy
Commentator: I. Steiner, Israel |
|
|
|
|
17:30-18:30 |
Debate: Treatment of bacterial meningitis: Empiric antibiotics or lumbar puncture: Which should be the first step?
Commentator: TBA |
ALZHEIMER'S DISEASE/DEMENTIA & INFECTIOUS DISEASES |
|
Sunday , October 11, 2009 |
|
|
|
|
NEUROPLASTICITY WITH THE GOODS AND THE BADS, FROM CLASSIC TO QUANTUM APPROACH |
| 08:30-10:30 |
|
| Capsule: |
Neuroplasticity is one of the powerful and harmonious realities of the brain aiming to maintain, adapt and regenerate neuronal circuitry. This amazing process is governed by molecular mechanisms but also by a complex mind-brain interface. Sometimes, faulty mechanisms might disturb the harmony.
|
|
Chairpersons:
|
B. El-Ad, Israel; K. von Wild, Germany
|
|
08:30-08:50
08:50-09:10
09:10-09:30
09:30-09:50
09:50-10:10
10:10-10:20
10:20-10:30 |
J. Schwartz, USA
D. Muresanu, Romania
O. Bajenaru, Romania
B.O. Popescu, Romania
Developing the next generation of treatment in AD
J. Bell, USA
Discussion |
|
|
|
|
10:30-11:00 |
Coffee Break |
|
|
|
|
|
NEUROLOGICAL DISEASES: FROM PATHOGENESIS TO MODERN THERAPY
|
| 11:00-13:00 |
|
| Capsule: |
The need to find noval therapies for neurological disease is hampered by poor understanding of underlying mechanisms and the adverse events associated with the more potent new drugs.
|
|
Chairpersons:
|
O. Bajenaru, Romania; R. Itzhaki, UK
|
|
11:00-11:15 |
|
|
|
|
| 11:15-11:30 |
G. Vithoulkas, Greece |
|
|
|
| 11:30-11:45 |
D. Blumenthal, Israel |
|
|
| 11:45-12:00 |
|
|
|
| 12:00-13:00 |
Debate: Temperature and barometric pressure are the most significant conditions for triggering migraine headache
Commentator: L. Griffiths, Australia |
|
|
|
13:00-13:30 |
POSTER AWARDS AND CLOSING CEREMONY |
|
Sunday , October 11, 2009 |
|
|
| Session 27 |
AD/PD BIOMARKERS |
| 08:30-10:30 |
|
| Capsule: |
The diagnosis of neurological disorders is severely hampered by the absence of reliable biomarkers. This session presents and compares currently known / clinically applied biomarkers in neurological disorders which can be identified and incorporated into clinical drug trials and elucidate proposed mechanisms of disease and drug action.
|
|
Chairpersons:
|
R. Ravid, The Netherlands; B. Solomon, Israel
|
|
08:30-08:45
08:45-09:00
09:00-09:15
09:15-09:30
09:30-09:45
09:45-10:00
10:00-10:15
10:15-10:30 |
E. Nordhoff, Germany
K. Marcus, Germany
D. Woitalla, Germany
G. Feuerstein, USA
H. Soares, USA
M. Memo, Italy
R. Ravid, The Netherlands |
|
|
| 10:30-11:00 |
Coffee Break |
|
|
| Session 28 |
AD: WHAT IS THE ENTITY AND CAN IT EVERY BE CURED? |
| 11:00-13:00 |
|
| Capsule: |
While the term AD is commonly used, there are difficulties in its definition. Attempts to treat patients with this form of dementia have so far failed. Is there hope?
|
|
Chairperson:
|
E. Giacobini, Switzerland; I. Rektorova, Czech Republic
|
|
11:00-12:00
|
Debate: Confirming the diagnosis of early AD/MCI with biomarkers is clinically useful
No: P.J. Visser, The Netherlands
Commentator: G. Ransmayr, Austria
|
| 12:00-12:30 |
F.C.C. Peng, Taiwan
|
| 12:30-12:40 |
P. Giannakopoulos, Greece
|
| 12:40-12:50 |
|
| 12:50-13:00 |
QEEG-neurometric analysis guided neurofeedback treatment in dementia: 9 cases "How neurometric analysis is important for the treatment of dementia as well as diagnosis?"
T. Surmeli, Turkey |
|
|
| 13:00-13:30 |
POSTER AWARDS AND CLOSING CEREMONY |
| Chairpersons: |
A.D. Korczyn, Israel; I. Rektor, Czech Republic |
|
|
|
|
WebStudio.co.il